Search

Your search keyword '"Lambertini, M."' showing total 632 results
Start Over Author "Lambertini, M." Search Limiters Available in Library Collection
632 results on '"Lambertini, M."'

2. Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)

Author

Agostinetto, E., Pfeiler, G., Hlauschek, D., Mayer, E.L., Lambertini, M., de Azambuja, E., Bellet-Ezquerra, M., Meisel, J.L., Rubovszky, G., Zdenkowski, N., Novik, Y., Ruiz-Borrego, M., Gelmon, K.A., Mamounas, E.P., Iwata, H., Lu, D.R., Soelkner, L., Fesl, C., Gnant, M., and DeMichele, A.

Published
2025
Full Text
View/download PDF

3. Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology

Author

Agostinetto, E., Bruzzone, M., Hamy, A.-S., Kim, H.J., Chiodi, C., Bernstein-Molho, R., Linn, S., Pogoda, K., Carrasco, E., Derouane, F., Bajpai, J., Nader-Marta, G., Lopetegui-Lia, N., Partridge, A.H., Cortesi, L., Rousset-Jablonski, C., Giugliano, F., Renaud, T., Ferrari, A., Paluch-Shimon, S., Fruscio, R., Cui, W., Wong, S.M., Vernieri, C., Ruddy, K.J., Dieci, M.V., Matikas, A., Rozenblit, M., Aguilar y Mendez, D., De Marchis, L., Borea, R., Puglisi, F., Pistelli, M., Kufel-Grabowska, J., Di Rocco, R., Mariamidze, E., Atzori, F., Kourie, H.R., Popovic, L., de Azambuja, E., Blondeaux, E., and Lambertini, M.

Published
2024
Full Text
View/download PDF

4. Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial

Author

Poggio, F., Blondeaux, E., Tagliamento, M., Perachino, M., Nardin, S., Conte, B., Giuliano, M., Arpino, G., De Laurentiis, M., Gravina, A., Bisagni, G., Rimanti, A., Turletti, A., Nisticò, C., Magnolfi, E., Gasparro, S., Fabi, A., Garrone, O., Alicicco, M.G., Urracci, Y., Poletti, P., Correale, P., Molinelli, C., Fozza, A., Puglisi, F., Colantuoni, G., Fregatti, P., Boni, L., Lambertini, M., and Del Mastro, L.

Published
2024
Full Text
View/download PDF

8. Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis

Author

Arecco, L., Blondeaux, E., Bruzzone, M., Latocca, M.M., Mariamidze, E., Begijanashvili, S., Sokolovic, E., Gentile, G., Scavone, G., Ottonello, S., Boutros, A., Vaz-Luis, I., Saura, C., Anderson, R.A., Demeestere, I., Azim, H.A., Jr, de Azambuja, E., Peccatori, F.A., Del Mastro, L., Partridge, A.H., and Lambertini, M.

Published
2023
Full Text
View/download PDF

13. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature

Author

Boutros, A., Bottini, A., Rossi, G., Tanda, E.T., Spagnolo, F., Barletta, G., Croce, E., Fava, P., Parisi, A., De Rosa, F., Palla, M., Marconcini, R., Ferrari, M., Grandis, M., Spallarossa, P., Sarocchi, M., Arboscello, E., Del Mastro, L., Lambertini, M., Pronzato, P., and Genova, C.

Published
2023
Full Text
View/download PDF

15. Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group

Author

Balic, Marija, Heibl, Sonja, Zabernigg, August Felix, Egle, Daniel, Sandholzer, Margit, Roitner, Florian, Andel, Johannes, Pichler, Petra, Hager, Christopher, Knauer, Michael, Hubalek, Michael, Bighin, Claudia, De Laurentiis, Michelino, De Placido, Sabino, Puglisi, Fabio, Boni, Luca, de Gregorio, Amelie, Degenhardt, Tom, Formisano, Luigi, Beelen, Karin, Robinson, Timothy, Fitzpatrick, Amanda, Dieras, Veronique, Muller, Volkmar, Gennari, Alessandra, Linn, Sabine, Braga, Sofia, Cortes, Javier, Palmieri, Carlo, Gampenrieder, S.P., Dezentjé, V., Lambertini, M., de Nonneville, A., Marhold, M., Le Du, F., Cortés Salgado, A., Alpuim Costa, D., Vaz Batista, M., Chic Ruché, N., Tinchon, C., Petzer, A., Blondeaux, E., Del Mastro, L., Targato, G., Bertucci, F., Gonçalves, A., Viret, F., Bartsch, R., Mannsbart, C., Deleuze, A., Robert, L., Saavedra Serrano, C., Gion Cortés, M., Sampaio-Alves, M., Vitorino, M., Pecen, L., Singer, C., Harbeck, N., Rinnerthaler, G., and Greil, R.

Published
2023
Full Text
View/download PDF

17. ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe

Author

Vaz-Luis, I., Masiero, M., Cavaletti, G., Cervantes, A., Chlebowski, R.T., Curigliano, G., Felip, E., Ferreira, A.R., Ganz, P.A., Hegarty, J., Jeon, J., Johansen, C., Joly, F., Jordan, K., Koczwara, B., Lagergren, P., Lambertini, M., Lenihan, D., Linardou, H., Loprinzi, C., Partridge, A.H., Rauh, S., Steindorf, K., van der Graaf, W., van de Poll-Franse, L., Pentheroudakis, G., Peters, S., and Pravettoni, G.

Published
2022
Full Text
View/download PDF

19. Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study

Author

Schettini, F, Blondeaux, E, Molinelli, C, Bas, R, Kim, H, Di Meglio, A, Bernstein Molho, R, Linn, S, Pogoda, K, Carrasco, E, Punie, K, Agostinetto, E, Lopetegui-Lia, N, Phillips, K, Toss, A, Rousset-Jablonski, C, Acheritogaray, M, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Dieci, M, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Puglisi, F, Vasconcelos de Matos, L, Marino, M, Teixeira, L, Graffeo, R, Rognone, A, Chirco, A, Antone, N, Abdou, Y, Marhold, M, Bozovic-Spasojevic, I, Cortes Salgado, A, Carmisciano, L, Bruzzone, M, Curigliano, G, Prat, A, Lambertini, M, Schettini F., Blondeaux E., Molinelli C., Bas R., Kim H. J., Di Meglio A., Bernstein Molho R., Linn S. C., Pogoda K., Carrasco E., Punie K., Agostinetto E., Lopetegui-Lia N., Phillips K. -A., Toss A., Rousset-Jablonski C., Acheritogaray M., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Dieci M. V., Matikas A., Rozenblit M., Villarreal-Garza C., De Marchis L., Puglisi F., Vasconcelos de Matos L., Marino M., Teixeira L., Graffeo R., Rognone A., Chirco A., Antone N., Abdou Y., Marhold M., Bozovic-Spasojevic I., Cortes Salgado A., Carmisciano L., Bruzzone M., Curigliano G., Prat A., Lambertini M., Schettini, F, Blondeaux, E, Molinelli, C, Bas, R, Kim, H, Di Meglio, A, Bernstein Molho, R, Linn, S, Pogoda, K, Carrasco, E, Punie, K, Agostinetto, E, Lopetegui-Lia, N, Phillips, K, Toss, A, Rousset-Jablonski, C, Acheritogaray, M, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Dieci, M, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Puglisi, F, Vasconcelos de Matos, L, Marino, M, Teixeira, L, Graffeo, R, Rognone, A, Chirco, A, Antone, N, Abdou, Y, Marhold, M, Bozovic-Spasojevic, I, Cortes Salgado, A, Carmisciano, L, Bruzzone, M, Curigliano, G, Prat, A, Lambertini, M, Schettini F., Blondeaux E., Molinelli C., Bas R., Kim H. J., Di Meglio A., Bernstein Molho R., Linn S. C., Pogoda K., Carrasco E., Punie K., Agostinetto E., Lopetegui-Lia N., Phillips K. -A., Toss A., Rousset-Jablonski C., Acheritogaray M., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Dieci M. V., Matikas A., Rozenblit M., Villarreal-Garza C., De Marchis L., Puglisi F., Vasconcelos de Matos L., Marino M., Teixeira L., Graffeo R., Rognone A., Chirco A., Antone N., Abdou Y., Marhold M., Bozovic-Spasojevic I., Cortes Salgado A., Carmisciano L., Bruzzone M., Curigliano G., Prat A., and Lambertini M.

Abstract

Background: Breast cancer (BC) in women aged ≤40 years carrying germline pathogenetic variants (PVs) in BRCA1/2 genes is infrequent but often associated with aggressive features. Human epidermal growth factor receptor 2 (HER2)-low-expressing BC has recently emerged as a novel therapeutic target but has not been characterized in this rare patient subset. Methods: Women aged ≤40 years with newly diagnosed early-stage HER2-negative BC (HER2-0 and HER2-low) and germline BRCA1/2 PVs from 78 health care centers worldwide were retrospectively included. Chi-square test and Student t-test were used to describe variable distribution between HER2-0 and HER2-low. Associations with HER2-low status were assessed with logistic regression. Kaplan–Meier method and Cox regression analysis were used to assess disease-free survival (DFS) and overall survival. Statistical significance was considered for p ≤.05. Results: Of 3547 included patients, 32.3% had HER2-low BC, representing 46.3% of hormone receptor–positive and 21.3% of triple-negative (TN) tumors. HER2-low vs. HER2-0 BC were more often of grade 1/2 (p <.001), hormone receptor–positive (p <.001), and node-positive (p =.003). BRCA2 PVs were more often associated with HER2-low than BRCA1 PVs (p <.001). HER2-low versus HER2-0 showed better DFS (hazard ratio [HR], 0.86; 95% CI, 0.76–0.97) in the overall population and more favorable DFS (HR, 0.78; 95% CI, 0.64–0.95) and overall survival (HR, 0.65; 95% CI, 0.46–0.93) in the TN subgroup. Luminal A–like tumors in HER2-low (p =.014) and TN and luminal A-like in HER2-0 (p =.019) showed the worst DFS. Conclusions: In young patients with HER2-negative BC and germline BRCA1/2 PVs, HER2-low disease was less frequent than expected and more frequently linked to BRCA2 PVs and associated with luminal-like disease. HER2-low status was associated with a modestly improved prognosis.

Published
2024

20. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study

Author

Lambertini, M, Blondeaux, E, Agostinetto, E, Hamy, A, Kim, H, Di Meglio, A, Molho, R, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Ignatiadis, M, Moore, H, Phillips, K, Toss, A, Rousset-Jablonski, C, Peccatori, F, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Ruddy, K, Dieci, M, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Del Mastro, L, Puglisi, F, Estevez-Diz, M, Rodriguez-Wallberg, K, Mrinakova, B, Meister, S, Livraghi, L, Clatot, F, Yerushalmi, R, De Angelis, C, Sanchez-Bayona, R, Meattini, I, Cichowska-Cwalinska, N, Berliere, M, Salama, M, De Giorgi, U, Sonnenblick, A, Chiodi, C, Lee, Y, Maria, C, Azim, H, Boni, L, Partridge, A, Lambertini M., Blondeaux E., Agostinetto E., Hamy A. -S., Kim H. J., Di Meglio A., Molho R. B., Hilbers F., Pogoda K., Carrasco E., Punie K., Bajpai J., Ignatiadis M., Moore H. C. F., Phillips K. -A., Toss A., Rousset-Jablonski C., Peccatori F. A., Renaud T., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Ruddy K. J., Dieci M. V., Matikas A., Rozenblit M., Villarreal-Garza C., De Marchis L., Del Mastro L., Puglisi F., Estevez-Diz M. D. P., Rodriguez-Wallberg K. A., Mrinakova B., Meister S., Livraghi L., Clatot F., Yerushalmi R., De Angelis C., Sanchez-Bayona R., Meattini I., Cichowska-Cwalinska N., Berliere M., Salama M., De Giorgi U., Sonnenblick A., Chiodi C., Lee Y. -J., Maria C., Azim H. A., Boni L., Partridge A. H., Lambertini, M, Blondeaux, E, Agostinetto, E, Hamy, A, Kim, H, Di Meglio, A, Molho, R, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Ignatiadis, M, Moore, H, Phillips, K, Toss, A, Rousset-Jablonski, C, Peccatori, F, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Ruddy, K, Dieci, M, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Del Mastro, L, Puglisi, F, Estevez-Diz, M, Rodriguez-Wallberg, K, Mrinakova, B, Meister, S, Livraghi, L, Clatot, F, Yerushalmi, R, De Angelis, C, Sanchez-Bayona, R, Meattini, I, Cichowska-Cwalinska, N, Berliere, M, Salama, M, De Giorgi, U, Sonnenblick, A, Chiodi, C, Lee, Y, Maria, C, Azim, H, Boni, L, Partridge, A, Lambertini M., Blondeaux E., Agostinetto E., Hamy A. -S., Kim H. J., Di Meglio A., Molho R. B., Hilbers F., Pogoda K., Carrasco E., Punie K., Bajpai J., Ignatiadis M., Moore H. C. F., Phillips K. -A., Toss A., Rousset-Jablonski C., Peccatori F. A., Renaud T., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Ruddy K. J., Dieci M. V., Matikas A., Rozenblit M., Villarreal-Garza C., De Marchis L., Del Mastro L., Puglisi F., Estevez-Diz M. D. P., Rodriguez-Wallberg K. A., Mrinakova B., Meister S., Livraghi L., Clatot F., Yerushalmi R., De Angelis C., Sanchez-Bayona R., Meattini I., Cichowska-Cwalinska N., Berliere M., Salama M., De Giorgi U., Sonnenblick A., Chiodi C., Lee Y. -J., Maria C., Azim H. A., Boni L., and Partridge A. H.

Abstract

(Abstracted from JAMA 2024;331(1):49-59 Individuals who are diagnosed with breast cancer at a young age are often carriers of a pathogenic variant in the BRCA1 or BRCA2 genes, and many young women in this situation are interested in preserving future fertility, if possible. Reproductive counseling in this situation can be complex due to the risk of passing on the variant, as well as the implications on their own fertility, as the mutation can impact ovarian reserve, fertility potential, and other factors.

Published
2024

21. Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers

Author

Arecco, L, Bruzzone, M, Bas, R, Kim, H, Di Meglio, A, Bernstein-Molho, R, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Agostinetto, E, Lopetegui-Lia, N, Partridge, A, Phillips, K, Toss, A, Rousset-Jablonski, C, Curigliano, G, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Couch, F, Dieci, M, Matikas, A, Rozenblit, M, Aguilar-y Mendez, D, De Marchis, L, Puglisi, F, Fabi, A, Graff, S, Witzel, I, Rodriguez Hernandez, A, Fontana, A, Pesce, R, Duchnowska, R, Pais, H, Sini, V, Sokolovic, E, de Azambuja, E, Ceppi, M, Blondeaux, E, Lambertini, M, Arecco L., Bruzzone M., Bas R., Kim H. J., Di Meglio A., Bernstein-Molho R., Hilbers F. S., Pogoda K., Carrasco E., Punie K., Bajpai J., Agostinetto E., Lopetegui-Lia N., Partridge A. H., Phillips K. A., Toss A., Rousset-Jablonski C., Curigliano G., Renaud T., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Couch F. J., Dieci M. V., Matikas A., Rozenblit M., Aguilar-y Mendez D., De Marchis L., Puglisi F., Fabi A., Graff S. L., Witzel I., Rodriguez Hernandez A., Fontana A., Pesce R., Duchnowska R., Pais H. L., Sini V., Sokolovic E., de Azambuja E., Ceppi M., Blondeaux E., Lambertini M., Arecco, L, Bruzzone, M, Bas, R, Kim, H, Di Meglio, A, Bernstein-Molho, R, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Agostinetto, E, Lopetegui-Lia, N, Partridge, A, Phillips, K, Toss, A, Rousset-Jablonski, C, Curigliano, G, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Couch, F, Dieci, M, Matikas, A, Rozenblit, M, Aguilar-y Mendez, D, De Marchis, L, Puglisi, F, Fabi, A, Graff, S, Witzel, I, Rodriguez Hernandez, A, Fontana, A, Pesce, R, Duchnowska, R, Pais, H, Sini, V, Sokolovic, E, de Azambuja, E, Ceppi, M, Blondeaux, E, Lambertini, M, Arecco L., Bruzzone M., Bas R., Kim H. J., Di Meglio A., Bernstein-Molho R., Hilbers F. S., Pogoda K., Carrasco E., Punie K., Bajpai J., Agostinetto E., Lopetegui-Lia N., Partridge A. H., Phillips K. A., Toss A., Rousset-Jablonski C., Curigliano G., Renaud T., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Couch F. J., Dieci M. V., Matikas A., Rozenblit M., Aguilar-y Mendez D., De Marchis L., Puglisi F., Fabi A., Graff S. L., Witzel I., Rodriguez Hernandez A., Fontana A., Pesce R., Duchnowska R., Pais H. L., Sini V., Sokolovic E., de Azambuja E., Ceppi M., Blondeaux E., and Lambertini M.

Abstract

Background: Hormone receptor expression is a known positive prognostic and predictive factor in breast cancer; however, limited evidence exists on its prognostic impact on prognosis of young patients harboring a pathogenic variant (PV) in the BRCA1 and/or BRCA2 genes. Patients and methods: This international, multicenter, retrospective cohort study included young patients (aged ≤40 years) diagnosed with invasive breast cancer and harboring germline PVs in BRCA genes. We investigated the impact of hormone receptor status on clinical behavior and outcomes of breast cancer. Outcomes of interest [disease-free survival (DFS), breast cancer-specific survival (BCSS), and overall survival (OS)] were first investigated according to hormone receptor expression (positive versus negative), and then according to breast cancer subtype [luminal A-like versus luminal B-like versus triple-negative versus human epidermal growth factor receptor 2 (HER2)-positive breast cancer]. Results: From 78 centers worldwide, 4709 BRCA carriers were included, of whom 2143 (45.5%) had hormone receptor-positive and 2566 (54.5%) hormone receptor-negative breast cancer. Median follow-up was 7.9 years. The rate of distant recurrences was higher in patients with hormone receptor-positive disease (13.1% versus 9.6%, P < 0.001), while the rate of second primary breast cancer was lower (9.1% versus 14.7%, P < 0.001) compared to patients with hormone receptor-negative disease. The 8-year DFS was 65.8% and 63.4% in patients with hormone receptor-positive and negative disease, respectively. The hazard ratio of hormone receptor-positive versus negative disease changed over time for DFS, BCSS, and OS (P < 0.05 for interaction of hormone receptor status and survival time). Patients with luminal A-like breast cancer had the worst long-term prognosis in terms of DFS compared to all the other subgroups (8-year DFS: 60.8% in luminal A-like versus 63.5% in triple-negative versus 65.5% in HER2-positive and 69

Published
2024

25. Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer

Author

Condorelli, M., Bruzzone, M., Ceppi, M., Ferrari, A., Grinshpun, A., Hamy, A.S., de Azambuja, E., Carrasco, E., Peccatori, F.A., Di Meglio, A., Paluch-Shimon, S., Poorvu, P.D., Venturelli, M., Rousset-Jablonski, C., Senechal, C., Livraghi, L., Ponzone, R., De Marchis, L., Pogoda, K., Sonnenblick, A., Villarreal-Garza, C., Córdoba, O., Teixeira, L., Clatot, F., Punie, K., Graffeo, R., Dieci, M.V., Pérez-Fidalgo, J.A., Duhoux, F.P., Puglisi, F., Ferreira, A.R., Blondeaux, E., Peretz-Yablonski, T., Caron, O., Saule, C., Ameye, L., Balmaña, J., Partridge, A.H., Azim, H.A., Demeestere, I., and Lambertini, M.

Published
2021
Full Text
View/download PDF

29. Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network

Author

Morgan, G., Tagliamento, M., Lambertini, M., Devnani, B., Westphalen, B., Dienstmann, R., Bozovic-Spasojevic, I., Calles, A., Criscitiello, C., Curioni, A., Garcia, A.M., Lamarca, A., Pilotto, S., Scheffler, M., Strijbos, M., Wong, R., de Azambuja, E., and Peters, S.

Published
2021
Full Text
View/download PDF

30. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study

Author

Schettini, F., Conte, B., Buono, G., De Placido, P., Parola, S., Griguolo, G., Fabi, A., Bighin, C., Riccardi, F., Cianniello, D., De Laurentiis, M., Puglisi, F., Pelizzari, G., Bonotto, M., Russo, S., Frassoldati, A., Pazzola, A., Montemurro, F., Lambertini, M., Guarneri, V., Cognetti, F., Locci, M., Generali, D., Conte, P., De Placido, S., Giuliano, M., Arpino, G., and Del Mastro, L.

Published
2021
Full Text
View/download PDF

33. VISTA: A Promising Target for Cancer Immunotherapy?

Author

Tagliamento M, Agostinetto E, Borea R, Brandão M, Poggio F, Addeo A, and Lambertini M

Subjects
vista, immune checkpoint inhibitor, immunotherapy, cancer, biomarker, Immunologic diseases. Allergy, RC581-607
Abstract

Marco Tagliamento,1,2 Elisa Agostinetto,3,4 Roberto Borea,2,5 Mariana Brandão,3 Francesca Poggio,6 Alfredo Addeo,7 Matteo Lambertini2,8 1Department of Medical Oncology, Medical Oncology 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 2Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, Italy; 3Institut Jules Bordet and Université Libre de Bruxelles (U.L.B), Brussels, Belgium; 4Medical Oncology and Hematology Unit, IRCCS Humanitas Clinical and Research Center and Humanitas University, Milan, Italy; 5Department of Medical Oncology, Medical Oncology 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 6Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 7Oncology Department, University Hospital of Geneva, Geneva, Switzerland; 8Department of Medical Oncology, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, ItalyCorrespondence: Marco TagliamentoDepartment of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, ItalyTel +39 010 5558902Email marco.tagliamento@edu.unige.itAbstract: Agents targeting the B7 family co-inhibitory receptors cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein-1 (PD-1), or its ligand (PD-L1), have a pivotal role in clinical practice. V-domain Ig suppressor of T-cell activation (VISTA) is a protein highly conserved between species, with a similar amino acid sequence to the B7 family members, characterized by a particularly structural homology to PD-1. It has been counted as an emerging target within the list of novel targetable immune checkpoints in oncology. Physiologically, VISTA exerts a regulatory function on the immune system at several levels, particularly by modulating T cells activation. Its altered activity plays a role in many autoimmune diseases, and its expression has been found to be prognostically implicated in different cancer types in preclinical models. We hereby present the main evidence on the value of VISTA as an immune checkpoint in solid and hematological malignancies. We also review its value as a potential target for cancer immunotherapy, by reporting the results of Phase I and II clinical trials assessing the use of drugs targeting VISTA. The complexity of its pathway, along with some unclear biological aspects concerning its molecular interactions, currently represent a limit to the applicability of VISTA as an effective biomarker for immunotherapy in oncology. A deeper characterization of this immune checkpoint may help defining its value within immune signatures of solid and hematological malignancies, and to design future therapeutic strategies.Keywords: VISTA, immune checkpoint, immunotherapy, cancer, biomarker

Published
2021

34. Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women

Author

Martelli V, Latocca MM, Ruelle T, Perachino M, Arecco L, Beshiri K, Razeti MG, Tagliamento M, Cosso M, Fregatti P, and Lambertini M

Subjects
breast cancer, fertility, young patient, oncofertility, premature ovarian insufficiency, anti-mullerian hormone, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Valentino Martelli,1,2 Maria Maddalena Latocca,1,2 Tommaso Ruelle,1,2 Marta Perachino,1,2 Luca Arecco,1,2 Kristi Beshiri,1,2 Maria Grazia Razeti,1,2 Marco Tagliamento,1,2 Maurizio Cosso,3 Piero Fregatti,4,5 Matteo Lambertini1,2 1Department of Medical Oncology, U.O.C Clinica Di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 2Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy; 3Department of Radiology, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 4U.O.C. Clinica Di Chirurgia Senologica, Department of Surgery, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 5Department of Integrated Diagnostic Surgical Sciences, School of Medicine, University of Genova, Genova, ItalyCorrespondence: Matteo LambertiniIRCCS Ospedale Policlinico San Martino, University of Genova, Largo Rosanna Benzi 10, Genova, 16132, ItalyTel +39 010 555 4254Fax + 39 010 555 6536Email matteo.lambertini@unige.itAbstract: Over the last several decades, improvements in breast cancer treatment have contributed to increased cure rates for women diagnosed with this malignancy. Consequently, great importance should be paid to the long-term side effects of systemic therapies. For young women (defined as per guideline ≤ 40 years at diagnosis) who undergo chemotherapy, one of the most impactful side effects on their quality of life is premature ovarian insufficiency (POI) leading to fertility-related problems and the side effects of early menopause. Regimens, type, and doses of chemotherapy, as well as the age of patients and their ovarian reserve at the time of treatment are major risk factors for treatment-induced POI. For these reasons, childbearing desire and preservation of ovarian function and/or fertility should be discussed with all premenopausal patients before planning the treatments. This manuscript summarizes the available fertility preservation techniques in breast cancer patients, the risk of treatment-induced POI with different anticancer treatments, and the possible procedures to prevent it. A special focus is paid to the role of oncofertility counseling, as a central part of the visit in this setting, during which the patient should receive all the information about the potential consequences of the disease and of the proposed treatment on her future life.Keywords: breast cancer, fertility, young patient, oncofertility, premature ovarian insufficiency, anti-Mullerian hormone

Published
2021

36. Pregnancy After Breast Cancer in Young BRCA Carriers

Author

Lambertini, M, Blondeaux, E, Agostinetto, E, Hamy, A-S, Kim, HJ, Di Meglio, A, Molho, RB, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Ignatiadis, M, Moore, HCF, Phillips, K-A, Toss, A, Rousset-Jablonski, C, Peccatori, FA, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, SM, Vernieri, C, Ruddy, KJ, Dieci, MV, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Del Mastro, L, Puglisi, F, Estevez-Diz, MDP, Rodriguez-Wallberg, KA, Mrinakova, B, Meister, S, Livraghi, L, Clatot, F, Yerushalmi, R, De Angelis, C, Sanchez-Bayona, R, Meattini, I, Cichowska-Cwalinska, N, Berliere, M, Salama, M, De Giorgi, U, Sonnenblick, A, Chiodi, C, Lee, Y-J, Maria, C, Azim, HA, Boni, L, Partridge, AH, Lambertini, M, Blondeaux, E, Agostinetto, E, Hamy, A-S, Kim, HJ, Di Meglio, A, Molho, RB, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Ignatiadis, M, Moore, HCF, Phillips, K-A, Toss, A, Rousset-Jablonski, C, Peccatori, FA, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, SM, Vernieri, C, Ruddy, KJ, Dieci, MV, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Del Mastro, L, Puglisi, F, Estevez-Diz, MDP, Rodriguez-Wallberg, KA, Mrinakova, B, Meister, S, Livraghi, L, Clatot, F, Yerushalmi, R, De Angelis, C, Sanchez-Bayona, R, Meattini, I, Cichowska-Cwalinska, N, Berliere, M, Salama, M, De Giorgi, U, Sonnenblick, A, Chiodi, C, Lee, Y-J, Maria, C, Azim, HA, Boni, L, and Partridge, AH

Abstract

IMPORTANCE: Young women with breast cancer who have germline pathogenic variants in BRCA1 or BRCA2 face unique challenges regarding fertility. Previous studies demonstrating the feasibility and safety of pregnancy in breast cancer survivors included limited data regarding BRCA carriers. OBJECTIVE: To investigate cumulative incidence of pregnancy and disease-free survival in young women who are BRCA carriers. DESIGN, SETTING, AND PARTICIPANTS: International, multicenter, hospital-based, retrospective cohort study conducted at 78 participating centers worldwide. The study included female participants diagnosed with invasive breast cancer at age 40 years or younger between January 2000 and December 2020 carrying germline pathogenic variants in BRCA1 and/or BRCA2. Last delivery was October 7, 2022; last follow-up was February 20, 2023. EXPOSURE: Pregnancy after breast cancer. MAIN OUTCOMES AND MEASURES: Primary end points were cumulative incidence of pregnancy after breast cancer and disease-free survival. Secondary end points were breast cancer-specific survival, overall survival, pregnancy, and fetal and obstetric outcomes. RESULTS: Of 4732 BRCA carriers included, 659 had at least 1 pregnancy after breast cancer and 4073 did not. Median age at diagnosis in the overall cohort was 35 years (IQR, 31-38 years). Cumulative incidence of pregnancy at 10 years was 22% (95% CI, 21%-24%), with a median time from breast cancer diagnosis to conception of 3.5 years (IQR, 2.2-5.3 years). Among the 659 patients who had a pregnancy, 45 (6.9%) and 63 (9.7%) had an induced abortion or a miscarriage, respectively. Of the 517 patients (79.7%) with a completed pregnancy, 406 (91.0%) delivered at term (≥37 weeks) and 54 (10.4%) had twins. Among the 470 infants born with known information on pregnancy complications, 4 (0.9%) had documented congenital anomalies. Median follow-up was 7.8 years (IQR, 4.5-12.6 years). No significant difference in disease-free survival was observed between patie

Published
2024

37. 163P Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study

Author

Schettini, F, Blondeaux, E, Molinelli, C, Bas, R, Kim, HJ, Di Meglio, A, Molho, RB, Linn, S, Pogoda, K, Carrasco, E, Punie, K, Agostinetto, E, Lia, NL, Phillips, K-A, Toss, A, Rousset-Jablonski, C, Acheritogaray, M, Curigliano, G, Prat, A, Lambertini, M, Schettini, F, Blondeaux, E, Molinelli, C, Bas, R, Kim, HJ, Di Meglio, A, Molho, RB, Linn, S, Pogoda, K, Carrasco, E, Punie, K, Agostinetto, E, Lia, NL, Phillips, K-A, Toss, A, Rousset-Jablonski, C, Acheritogaray, M, Curigliano, G, Prat, A, and Lambertini, M

Published
2024

38. 160P Characteristics and outcomes of young breast cancer patients harboring BRCA pathogenic variants according to histologic subtype

Author

Agostinetto, E, Bruzzone, M, Hamy-Petit, A-S, Kim, HJ, Chiodi, CK, Molho, RB, Linn, S, Pogoda, K, Carrasco, E, Derouane, F, Bajpai, J, Lia, NL, Partridge, AH, Phillips, K-A, Toss, A, Rousset-Jablonski, C, Giugliano, F, de Azambuja, E, Blondeaux, E, Lambertini, M, Agostinetto, E, Bruzzone, M, Hamy-Petit, A-S, Kim, HJ, Chiodi, CK, Molho, RB, Linn, S, Pogoda, K, Carrasco, E, Derouane, F, Bajpai, J, Lia, NL, Partridge, AH, Phillips, K-A, Toss, A, Rousset-Jablonski, C, Giugliano, F, de Azambuja, E, Blondeaux, E, and Lambertini, M

Published
2024

39. Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology

Author

Agostinetto, E, Bruzzone, M, Hamy, A, Kim, H, Chiodi, C, Bernstein-Molho, R, Linn, S, Pogoda, K, Carrasco, E, Derouane, F, Bajpai, J, Nader-Marta, G, Lopetegui-Lia, N, Partridge, A, Cortesi, L, Rousset-Jablonski, C, Giugliano, F, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Ruddy, K, Dieci, M, Matikas, A, Rozenblit, M, Aguilar Y Mendez, D, De Marchis, L, Borea, R, Puglisi, F, Pistelli, M, Kufel-Grabowska, J, Di Rocco, R, Mariamidze, E, Atzori, F, Kourie, H, Popovic, L, de Azambuja, E, Blondeaux, E, Lambertini, M, Hamy, A-S, Kim, H J, Partridge, A H, Wong, S M, Ruddy, K J, Dieci, M V, Kourie, H R, Agostinetto, E, Bruzzone, M, Hamy, A, Kim, H, Chiodi, C, Bernstein-Molho, R, Linn, S, Pogoda, K, Carrasco, E, Derouane, F, Bajpai, J, Nader-Marta, G, Lopetegui-Lia, N, Partridge, A, Cortesi, L, Rousset-Jablonski, C, Giugliano, F, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Ruddy, K, Dieci, M, Matikas, A, Rozenblit, M, Aguilar Y Mendez, D, De Marchis, L, Borea, R, Puglisi, F, Pistelli, M, Kufel-Grabowska, J, Di Rocco, R, Mariamidze, E, Atzori, F, Kourie, H, Popovic, L, de Azambuja, E, Blondeaux, E, Lambertini, M, Hamy, A-S, Kim, H J, Partridge, A H, Wong, S M, Ruddy, K J, Dieci, M V, and Kourie, H R

Abstract

Background: Young women with breast cancer (BC) have an increased chance of carrying germline BRCA pathogenic variants (PVs). Limited data exist on the prognostic impact of tumor histology (i.e. ductal versus lobular) in hereditary breast cancer. Methods: This multicenter retrospective cohort study included women aged ≤40 years with early-stage breast cancer diagnosed between January 2000 and December 2020 and known to carry germline PVs in BRCA1/2. Histology was locally assessed in each center. The Kaplan-Meier method and Cox regression analysis were used to assess disease-free survival and overall survival. Results: Of 4628 patients included from 78 centers worldwide, 3969 (86%) had pure ductal, 135 (3%) pure lobular, and 524 (11%) other histologies. Compared with ductal tumors, lobular tumors were more often grade 1/2 (57.7% versus 22.1%), stage III (29.6% versus 18.5%), and luminal A-like (42.2% versus 12.2%). Lobular tumors were more often associated with BRCA2 PVs (71.1% BRCA2), while ductal tumors were more often associated with BRCA1 PVs (65.7% BRCA1). Patients with lobular tumors more often had mastectomy (68.9% versus 58.3%), and less often received chemotherapy (83.7% versus 92.9%). With a median follow-up of 7.8 years, no significant differences were observed in disease-free survival (adjusted hazard ratio 1.01, 95% confidence interval 0.74-1.37) or overall survival (hazard ratio 0.96, 95% confidence interval 0.62-1.50) between patients with ductal versus lobular tumors. No significant survival differences were observed according to specific BRCA gene, breast cancer subtype, or body mass index. Conclusions: In this large global cohort of young BRCA carriers with breast cancer, the incidence of pure lobular histology was low and associated with higher disease stage at diagnosis, luminal-like disease and BRCA2 PVs. Histology did not appear to impact prognosis.

Published
2024

40. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis

Author

Ferreira, A.R., Di Meglio, A., Pistilli, B., Gbenou, A.S., El-Mouhebb, M., Dauchy, S., Charles, C., Joly, F., Everhard, S., Lambertini, M., Coutant, C., Cottu, P., Lerebours, F., Petit, T., Dalenc, F., Rouanet, P., Arnaud, A., Martin, A., Berille, J., Ganz, P.A., Partridge, A.H., Delaloge, S., Michiels, S., Andre, F., and Vaz-Luis, I.

Published
2019
Full Text
View/download PDF

42. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline ☆

Author

Sessa, C, Balmana, J, Bober, S, Cardoso, M, Colombo, N, Curigliano, G, Domchek, S, Evans, D, Fischerova, D, Harbeck, N, Kuhl, C, Lemley, B, Levy-Lahad, E, Lambertini, M, Ledermann, J, Loibl, S, Phillips, K, Paluch-Shimon, S, Sessa C., Balmana J., Bober S. L., Cardoso M. J., Colombo N., Curigliano G., Domchek S. M., Evans D. G., Fischerova D., Harbeck N., Kuhl C., Lemley B., Levy-Lahad E., Lambertini M., Ledermann J. A., Loibl S., Phillips K. -A., Paluch-Shimon S., Sessa, C, Balmana, J, Bober, S, Cardoso, M, Colombo, N, Curigliano, G, Domchek, S, Evans, D, Fischerova, D, Harbeck, N, Kuhl, C, Lemley, B, Levy-Lahad, E, Lambertini, M, Ledermann, J, Loibl, S, Phillips, K, Paluch-Shimon, S, Sessa C., Balmana J., Bober S. L., Cardoso M. J., Colombo N., Curigliano G., Domchek S. M., Evans D. G., Fischerova D., Harbeck N., Kuhl C., Lemley B., Levy-Lahad E., Lambertini M., Ledermann J. A., Loibl S., Phillips K. -A., and Paluch-Shimon S.

Published
2023

43. Triple-negative breast cancer: current perspective on the evolving therapeutic landscape

Author

Mehanna J, Haddad FGH, Eid R, Lambertini M, and Kourie HR

Subjects
breast cancer, triple negative, immunotherapy, PARP inhibitors, Gynecology and obstetrics, RG1-991
Abstract

Joe Mehanna,1 Fady GH Haddad,1 Roland Eid,1 Matteo Lambertini,2,3 Hampig Raphael Kourie11Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon; 2Department of Medical Oncology, U.O.C. Clinica Di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 3Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, ItalyAbstract: Triple-negative breast cancer (TNBC) is known to have a poor prognosis and limited treatment options, namely chemotherapy. Different molecular studies have recently classified TNBC into different subtypes opening the door to potential new-targeted treatment options. In this review, we discuss the current standard of care in the treatment of TNBC in the neoadjuvant, adjuvant and metastatic settings. In addition, we summarize the ongoing phase III clinical trials evaluating different associations between the 3 pillars of anticancer treatment: chemotherapy, targeted therapy and immunotherapy.Keywords: breast cancer, triple-negative, immunotherapy, PARP inhibitors

Published
2019

48. Young oncologists’ perspective on the role and future of the clinician-scientist in oncology

Author

Lim, K.H.J., primary, Westphalen, C.B., additional, Berghoff, A.S., additional, Cardone, C., additional, Connolly, E.A., additional, Güven, D.C., additional, Kfoury, M., additional, Kocakavuk, E., additional, Mandó, P., additional, Mariamidze, E., additional, Matikas, A., additional, Moutafi, M., additional, Oing, C., additional, Pihlak, R., additional, Punie, K., additional, Sánchez-Bayona, R., additional, Sobczuk, P., additional, Starzer, A.M., additional, Tečić Vuger, A., additional, Zhu, H., additional, Cruz-Ordinario, M.V.B., additional, Altuna, S.C., additional, Canário, R., additional, Vuylsteke, P., additional, Banerjee, S., additional, de Azambuja, E., additional, Cervantes, A., additional, Lambertini, M., additional, Mateo, J., additional, and Amaral, T., additional

Published
2023
Full Text
View/download PDF

49. O-277 Safety of pregnancy after early breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis

Author

Arecco, L, primary, Blondeaux, E, additional, Mariamidze, E, additional, Begijanashvili, S, additional, Sokolovic, E, additional, Scavone, G, additional, Ottonello, S, additional, Vaz-Luis, I, additional, Sàura, C, additional, Anderson, R A, additional, Demeestere, I, additional, Azim, H A, additional, Peccatori, F A, additional, Partridge, A H, additional, and Lambertini, M, additional

Published
2023
Full Text
View/download PDF

50. 101P Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: An individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies

Author

Lambertini, M., primary, Blondeaux, E., additional, Bisagni, G., additional, Mura, S., additional, de Placido, S., additional, De Laurentiis, M., additional, Fabi, A., additional, Rimanti, A., additional, Michelotti, A., additional, Mansutti, M., additional, Russo, A., additional, Montemurro, F., additional, Frassoldati, A., additional, Durando, A., additional, Gori, S., additional, Turletti, A., additional, Tamberi, S., additional, Urracci, Y., additional, de Azambuja, E., additional, and Del Mastro, L., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results